Drug Trial Radar · NCT01922102
Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
Last checked: Nov 20, 2026Latest source record: Jun 24, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
457
Actual
Start
Sep 11, 2013
Primary completion
Sep 14, 2016
Study completion Sep 14, 2016
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 14, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia (PM)
Conditions
- Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)
Interventions
Ranibizumab 0.5mgDrug
0.5 mg ranibizumab (intravitreal injections)
Ranibizumab 0.5 mgDrug
0.5 mg ranibizumab (intravitreal injections)
Verteporfin PDTDrug
Verteporfin for intravenous injection delivered by intravenous infusion followed by the light application
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 3Time frame: From Baseline to Month 3
Locations
47 sites in 6 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Chongqing, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Beijing, Beijing Municipality, China
Novartis Investigative Site
Beijing, Beijing Municipality, China
Novartis Investigative Site
Chongqing, Chongqing Municipality, China
Novartis Investigative Site
Shantou, Guangdong, China
Novartis Investigative Site
Harbin, Heilongjiang, China
Novartis Investigative Site
Wuhan, Hubei, China
Novartis Investigative Site
Wuhan, Hubei, China
Novartis Investigative Site
Changsha, Hunan, China
Novartis Investigative Site
Changsha, Hunan, China
Novartis Investigative Site
Nanjing, Jiangsu, China
Novartis Investigative Site
Nanjing, Jiangsu, China
Novartis Investigative Site
Wuxi, Jiangsu, China
Novartis Investigative Site
Nanchang, Jiangxi, China
Novartis Investigative Site
Qingdao, Shandong, China
Novartis Investigative Site
Xi’an, Shanxi, China
Novartis Investigative Site
Chengdu, Sichuan, China
Novartis Investigative Site
Tianjin, Tianjin Municipality, China
Novartis Investigative Site
Tianjin, Tianjin Municipality, China
Novartis Investigative Site
Hangzhou, Zhejiang, China
Novartis Investigative Site
Wenzhou, Zhejiang, China
Novartis Investigative Site
Hong Kong, Hong Kong
Novartis Investigative Site
Angamaly, India
Novartis Investigative Site
New Delhi, India
Novartis Investigative Site
Chandīgarh, Haryana, India
Novartis Investigative Site
Bangalore, Karnataka, India
Novartis Investigative Site
Vanchiyoor, Kerala, India
Novartis Investigative Site
Bhubaneswar, Odisha, India
Novartis Investigative Site
Chennai, Tamil Nadu, India
Novartis Investigative Site
Chennai, Tamil Nadu, India
Novartis Investigative Site
Coimbatore, Tamil Nadu, India
Novartis Investigative Site
Hyderabad, Telangana, India
Novartis Investigative Site
Manila, National Capital Region, Philippines
Novartis Investigative Site
Manila, National Capital Region, Philippines
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.